Project description
Oral drug absorption for the ageing population
Although the elderly population (>65 years old) is the group that suffers most from chronic disorders, they are paradoxically not considered in the drug development process, which only employs data from healthy adults aged 18–55. To address this limitation, the EU-funded AGePOP project will investigate the physiological gastrointestinal tract alterations associated with ageing and improve oral drug effectiveness. Through an interdisciplinary training programme, the project will help early-stage researchers study the characteristics of the gastrointestinal tract of older people and geriatric patients, thereby guiding the future development of drugs suitable for this age group.
Objective
The advanced age population (>65y) makes up ~20% of the total population in Europe, is the main carrier of chronic diseases and the major end-user group of medications. Yet, despite an ageing society, these end-users are entirely disregarded in the drug development process, which considers only healthy adults aged 18-55. Effective absorption of oral drugs, which remain the preferred form of administration, relies on a sound knowledge of the physiological alterations associated with ageing and of the characteristics of the gastrointestinal (GI) tract in older subjects. Nonetheless, both the knowledge and the experts in this area are lacking. The AGePOP European Training Network (ETN) will boost Europe’s innovation capacity and leadership in oral drug development. Its multisectoral approach will train 11 Early Stage Researchers (ESRs) to become the future experts in drug development for the advanced age population, shedding a much needed light on the needs of our ageing society. With an open science philosophy and a multidisciplinary strategy, the ESRs will collect the first ever dataset of physiological characteristics of the GI tract of older people and geriatric patients, developing novel in vitro and in silico tools, e.g. a mobile test kit to evaluate gastric emptying kinetics and an absorption risk calculator to predict adverse effects from altered pharmacokinetics. Complementary training in transferable, business and wider horizon skills will equip the ESRs with an all-rounded skillset. AGePOP is a network of 6 Beneficiaries and 7 Partner Organisations from 5 European countries. Its 3 academic partners with research excellence in oral drug products synergise with renowned clinicians and researchers from 8 leading pharma companies and 1 SME specialised in ETN training. Building on long-standing collaborations, the consortium will provide 11 ESRs with a unique Europe-wide learning experience, preparing them to lead their future careers with confidence and success.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences basic medicine pharmacology and pharmacy pharmacokinetics
- humanities philosophy, ethics and religion philosophy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-ITN-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
10 561 ATHINA
Greece
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.